Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01001923 · ClinicalTrials.gov registry record · Phase 2
Single Injection of REGN475/SAR164877 in the Treatment of Chronic Pancreatitis Pain
A Phase 2 study, sponsored by Regeneron Pharmaceuticals.
- Terminated
- Registry status
- Phase 2
- Development phase
- 15
- Enrollment target
NCT01001923 is a Phase 2 study that was terminated before completion, run by Regeneron Pharmaceuticals. The registered enrollment target is 15 participants.
The verdict
NCT01001923, a Phase 2 study, was terminated before completion, sponsored by Regeneron Pharmaceuticals.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 15 participants
- Enrollment target
Study Summary
Primary objective was to demonstrate the activity of REGN475/SAR164877 in reducing the pain associated with chronic pancreatitis. Secondary objectives were: * to assess the safety and tolerability of REGN475/SAR164877 in patients with chronic pancreatitis pain; * to characterize the pharmacokinetic, pharmacodynamic, and immunogenicity profiles of REGN475/SAR164877 in this population; * to measure the change in the total daily dose of rescue medications required.
Interventions
- DRUG REGN475/SAR164877
- DRUG Placebo (for REGN475/SAR164877)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 15 participants |
| Start Date | 2009-12 |
| Est. Completion | 2011-01 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01001923
The ClinicalTrials.gov registry entry for NCT01001923 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 15 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Regeneron Pharmaceuticals, which has 280 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which REGN475/SAR164877 is the first listed.
NCT01001923 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01001923 about?
NCT01001923 is a clinical study titled "Single Injection of REGN475/SAR164877 in the Treatment of Chronic Pancreatitis Pain". Primary objective was to demonstrate the activity of REGN475/SAR164877 in reducing the pain associated with chronic pancreatitis. Secondary objectives were: * to assess the safety and tolerability of REGN475/SAR164877 in patients with chronic pancreatitis pain; * to characterize the pharmacokineti...
What is the current status of trial NCT01001923?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 15 participants. The study started on 2009-12. Estimated completion is 2011-01.
What interventions are being tested in trial NCT01001923?
The interventions under investigation include: REGN475/SAR164877 (DRUG), Placebo (for REGN475/SAR164877) (DRUG).
Who is sponsoring clinical trial NCT01001923?
This trial is sponsored by Regeneron Pharmaceuticals, which has 280 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.